(70, 71) In one published case of grade 3 CRS and grade 4 ICANS observed after anti-CD19 CAR T cell therapy for LBCL despite treatment with four doses of tocilizumab and high-dose glucocorticoids, treatment with dasatinib 100 mg daily for seven days resulted in substantial clinical improvement. This evidence concerns the gene CD19 and congenital rubella syndrome.